{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:49:18Z","timestamp":1787060958465,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:00:00Z","timestamp":1757203200000},"content-version":"am","delay-in-days":310,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ygyno.2024.08.019","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T23:22:52Z","timestamp":1725664972000},"page":"236-242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Impact of adjuvant therapy on oncologic outcomes in uterine-confined clear cell carcinoma of the endometrium"],"prefix":"10.1016","volume":"190","author":[{"given":"Eric","family":"Rios-Doria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana Pedra","family":"Nobre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dib","family":"Sassine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretchen","family":"Glaser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ane Gerda","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beyhan","family":"Ataseven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"du Bois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Makker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaled","family":"Alektiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Mario M.","family":"Leitao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadeem R.","family":"Abu-Rustum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2024.08.019_bb0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2024.08.019_bb0010","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1006\/gyno.1999.5505","article-title":"Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma","volume":"74","author":"Cirisano","year":"1999","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.08.019_bb0015","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/sj.bjc.6603012","article-title":"Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers","volume":"94","author":"Hamilton","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2024.08.019_bb0020","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0090-8258(90)90279-T","article-title":"Clear cell carcinoma of the endometrium: a histopathological and clinical study of 97 cases","volume":"40","author":"Abeler","year":"1991","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.08.019_bb0025","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S1470-2045(17)30068-2","article-title":"A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study","volume":"18","author":"Rossi","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2024.08.019_bb0030","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.ygyno.2019.03.254","article-title":"Sentinel node mapping vs. lymphadenectomy in endometrial cancer: a systematic review and meta-analysis","volume":"153","author":"Bogani","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.08.019_bb0035","doi-asserted-by":"crossref","first-page":"367.e1","DOI":"10.1016\/j.ajog.2021.05.034","article-title":"Sentinel lymph node biopsy in high-grade endometrial cancer: a systematic review and meta-analysis of performance characteristics","volume":"225","author":"Marchocki","year":"2021","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2024.08.019_bb0040","unstructured":"National Comprehensive Cancer Network. Uterine Neoplasms (Version 2.2023) n.d. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/uterine.pdf. (accessed July 14, 2023)."},{"key":"10.1016\/j.ygyno.2024.08.019_bb0045","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ygyno.2019.08.031","article-title":"Contemporary management of uterine clear cell carcinoma: a Society of Gynecologic Oncology (SGO) review and recommendation","volume":"155","author":"Olawaiye","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.08.019_bb0050","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ygyno.2022.12.024","article-title":"The role of adjuvant treatment for early-stage uterine clear cell carcinomas","volume":"170","author":"Orellana","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.08.019_bb0055","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/IGC.0000000000000643","article-title":"Role of adjuvant therapy for stage IA serous and clear cell uterine cancer: is observation a valid strategy?","volume":"26","author":"Velker","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2024.08.019_bb0060","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ygyno.2005.08.037","article-title":"Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the gynecologic oncology group","volume":"100","author":"Sutton","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.08.019_bb0065","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/107327480901600107","article-title":"Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes","volume":"16","author":"Mendivil","year":"2009","journal-title":"Cancer Control"},{"key":"10.1016\/j.ygyno.2024.08.019_bb0070","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1200\/JCO.18.01575","article-title":"Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel\/carboplatin in high-intermediate and high-risk early stage endometrial cancer","volume":"37","author":"Randall","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.08.019_bb0075","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa1813181","article-title":"Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer","volume":"380","author":"Matei","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2024.08.019_bb0080","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1470-2045(18)30079-2","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial","volume":"19","author":"de Boer","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2024.08.019_bb0085","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ygyno.2007.11.008","article-title":"Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multi-institutional review","volume":"108","author":"Thomas","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.08.019_bb0090","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ygyno.2017.11.010","article-title":"Adjuvant therapy in patients with clear cell endometrial carcinoma: an analysis of the National Cancer Database","volume":"148","author":"Nieto","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.08.019_bb0095","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijgo.2009.02.012","article-title":"Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium","volume":"105","author":"Pecorelli","year":"2009","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.ygyno.2024.08.019_bb0100","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.brachy.2018.08.015","article-title":"Comparison of outcomes in early-stage uterine clear cell carcinoma and serous carcinoma","volume":"18","author":"Zhang","year":"2019","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ygyno.2024.08.019_bb0105","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.ygyno.2013.03.011","article-title":"Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas","volume":"129","author":"Ayeni","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.08.019_bb0110","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41572-021-00324-8","article-title":"Endometrial cancer","volume":"7","author":"Makker","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ygyno.2024.08.019_bb0115","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2024.08.019_bb0120","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ygyno.2023.05.059","article-title":"Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinoma","volume":"174","author":"Rios-Doria","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.08.019_bb0125","doi-asserted-by":"crossref","first-page":"1147394","DOI":"10.3389\/fonc.2023.1147394","article-title":"The role of TCGA molecular classification in clear cell endometrial carcinoma","volume":"13","author":"Tang","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ygyno.2024.08.019_bb0130","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.humpath.2019.06.005","article-title":"Clear cell carcinoma of the endometrium: an immunohistochemical and molecular analysis of 45 cases","volume":"92","author":"Zannoni","year":"2019","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ygyno.2024.08.019_bb0135","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/path.4947","article-title":"The genetic landscape of endometrial clear cell carcinomas","volume":"243","author":"DeLair","year":"2017","journal-title":"J. Pathol."},{"key":"10.1016\/j.ygyno.2024.08.019_bb0140","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/his.13976","article-title":"Clear cell endometrial carcinoma and the TCGA classification","volume":"76","author":"Travaglino","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.ygyno.2024.08.019_bb0145","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int. J. Gynaecol. Obstet."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824010874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824010874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T21:06:16Z","timestamp":1730927176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825824010874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":29,"alternative-id":["S0090825824010874"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.08.019","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of adjuvant therapy on oncologic outcomes in uterine-confined clear cell carcinoma of the endometrium","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}